BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 14, Issue 2
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (7187)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.
Item 
Count 
PDF279
HTML3953
Figures (1-2)435
Tables (1-1)457
 Sum=5124
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse278
Download713
 Sum=991
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse196
Download607
 Sum=803
Jun 20, 2024 (publication date) through May 2, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Experimental Medicine
ISSN
2220-315x
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2024.
World J Exp Med. Jun 20, 2024; 14(2): 92558
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.92558
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Chemical structures of halichondrin B and eribulin mesylate. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of halichondrin B Citation: Swami U, Shah U, Goel S. Eribulin in Cancer Treatment. Mar Drugs 2015; 13: 5016-5058. Copyright© The Authors 2015. Published by MDPI. The authors have obtained the permission for figure using from the copyright holder (Supplementary material).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Eribulin non-mitotic mechanisms of action in cancer. Eribulin induces phenotypic reversal of epithelial to mesenchymal transition, decreases proportions of cancer stem cells, reduces the immunosuppressive tumour microenvironment and promotes vascular remodelling.
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.